title: Novel ultrasound and DCE-MRI analyses after antiangiogenic treatment with a selective VEGF receptor inhibitor.
abstract: We report a comparison between tumor perfusion estimates acquired using contrast-enhanced MRI and motion-corrected contrast-enhanced ultrasound before and after treatment with AG-028262, a potent vascular endothelial growth factor receptor tyrosine kinase inhibitor. Antiangiogenic activity was determined by assessing weekly ultrasound and MRI images of rats with bilateral hind flank mammary adenocarcinomas before and after treatment with AG-028262. Images were acquired with a spoiled gradient, 1.5 T magnetic resonance sequence and a destruction-replenishment ultrasound protocol. For ultrasound, a time to 80% contrast replenishment was calculated for each tumor voxel; for MR imaging, a measure of local flow rate was estimated from a linear fit of minimum to maximum intensities. AG-028262 significantly decreased tumor growth and increased the time required to replenish tumor voxels with an ultrasound contrast agent from 2.66 to 4.54 s and to fill with an MR contrast agent from 29.5 to 50.8 s. Measures of flow rate derived from MRI and ultrasound demonstrated a positive linear correlation of r2 = 0.86.
authors.affiliation: Department of Biomedical Engineering, University of California, Davis, CA 95327, USA.
authors.forename: Katherine D
authors.initials: KD
authors.lastname: Watson
authors.forename: Xiaowen
authors.initials: X
authors.lastname: Hu
authors.forename: Chun-Yen
authors.initials: CY
authors.lastname: Lai
authors.forename: Heather A
authors.initials: HA
authors.lastname: Lindfors
authors.forename: Dana D
authors.initials: DD
authors.lastname: Hu-Lowe
authors.forename: Theresa A
authors.initials: TA
authors.lastname: Tuthill
authors.forename: David R
authors.initials: DR
authors.lastname: Shalinsky
authors.forename: Katherine W
authors.initials: KW
authors.lastname: Ferrara
mesh_terms: D000230:Adenocarcinoma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000818:Animals; D045744:Cell Line, Tumor; D038524:Diffusion Magnetic Resonance Imaging / Q000379:methods*; D005260:Female; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D051381:Rats; D011916:Rats, Inbred F344; D040262:Receptors, Vascular Endothelial Growth Factor / Q000187:drug effects; D016896:Treatment Outcome; D014463:Ultrasonography / Q000379:methods*
chemical_list: D020533:Angiogenesis Inhibitors; D040262:Receptors, Vascular Endothelial Growth Factor